Arcellx (NASDAQ:ACLX) Cut to “Hold” at Evercore

Evercore downgraded shares of Arcellx (NASDAQ:ACLX) from a strong-buy rating to a hold rating in a research report sent to investors on Monday morning,Zacks.com reports.

Several other equities analysts have also issued reports on ACLX. Wells Fargo & Company lowered Arcellx from an “overweight” rating to an “equal weight” rating and set a $115.00 price target on the stock. in a research note on Monday. William Blair cut Arcellx from a “strong-buy” rating to a “hold” rating in a report on Monday. HC Wainwright downgraded shares of Arcellx from a “buy” rating to a “neutral” rating and set a $115.00 target price on the stock. in a research report on Monday. Guggenheim reaffirmed a “buy” rating on shares of Arcellx in a report on Monday, November 24th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Arcellx in a research report on Wednesday, January 21st. One research analyst has rated the stock with a Buy rating, sixteen have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $111.87.

Arcellx Price Performance

ACLX opened at $113.76 on Monday. The stock has a market capitalization of $6.58 billion, a P/E ratio of -28.95 and a beta of 0.36. The company’s 50 day simple moving average is $69.82 and its 200-day simple moving average is $75.65. Arcellx has a one year low of $47.86 and a one year high of $114.26.

Insider Activity at Arcellx

In other Arcellx news, insider Christopher Heery sold 5,882 shares of Arcellx stock in a transaction dated Wednesday, January 14th. The stock was sold at an average price of $68.51, for a total transaction of $402,975.82. Following the transaction, the insider directly owned 23,749 shares in the company, valued at approximately $1,627,043.99. The trade was a 19.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In the last three months, insiders have sold 19,450 shares of company stock valued at $1,283,477. 8.35% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Arcellx

Several institutional investors have recently modified their holdings of the business. T. Rowe Price Investment Management Inc. grew its position in shares of Arcellx by 66.2% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 10,560,425 shares of the company’s stock valued at $688,540,000 after purchasing an additional 4,208,069 shares during the period. Invesco Ltd. lifted its stake in Arcellx by 19.9% in the fourth quarter. Invesco Ltd. now owns 40,372 shares of the company’s stock valued at $2,632,000 after buying an additional 6,704 shares in the last quarter. Mercer Global Advisors Inc. ADV lifted its position in Arcellx by 19.0% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 4,107 shares of the company’s stock valued at $268,000 after acquiring an additional 655 shares in the last quarter. XTX Topco Ltd acquired a new position in Arcellx in the 4th quarter worth $4,732,000. Finally, Vestal Point Capital LP raised its stake in shares of Arcellx by 134.0% in the 4th quarter. Vestal Point Capital LP now owns 2,925,000 shares of the company’s stock valued at $190,710,000 after purchasing an additional 1,675,000 shares during the period. Institutional investors own 96.03% of the company’s stock.

Key Arcellx News

Here are the key news stories impacting Arcellx this week:

• Positive Sentiment: Gilead agreed to acquire Arcellx for up to $7.8 billion, a transformational M&A outcome that explains much of the upward price pressure by crystallizing acquisition value for ACLX shareholders. Gilead to buy Arcellx
• Neutral Sentiment: HC Wainwright published a FY2030 EPS projection (very bullish numerically) with a $115 price target but maintained a “Neutral” rating — the target is close to the current trade and offers limited additional upside. (Source: market research note)
• Neutral Sentiment: Short‑interest data reported for late February shows 0 shares and a 0.0 days‑to‑cover figure, which appears to be a data anomaly and therefore provides no clear signal about short‑seller pressure.
• Negative Sentiment: A broad set of sell‑side shops (Leerink, Evercore, Needham, Wells Fargo, Citigroup, Truist, Canaccord and others) moved ACLX toward “Hold” from stronger stances (strong‑buy/buy/outperform). Several firms cut or trimmed price targets (Truist cut to $120 from $134; others adjusted targets and ratings), creating short‑term headwinds and mixed sell signals despite the M&A news. Citigroup downgrades Arcellx Analyst coverage roundup

About Arcellx

Arcellx, Inc (NASDAQ: ACLX) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation cell therapies for oncology and autoimmune diseases. The company’s proprietary ARC-SparX™ platform is designed to enable precise control over cell-surface receptor activation and to improve the safety, efficacy and durability of adoptive cell therapies. Leveraging this technology, Arcellx engineers immune cells with modular antigen-binding domains that can be exchanged to target a variety of disease-associated markers.

The company’s pipeline comprises multiple wholly owned programs in hematologic malignancies and solid tumors at various stages of preclinical and clinical development.